[
  {
    "ts": null,
    "headline": "Columbia Dividend Income Fund Q3 2024 Commentary",
    "summary": "Institutional Class shares of Columbia Dividend Income Fund returned 8.12% for the \nquarter ending September 30, 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=00f44478a7c2c5c5bdfac13b4f48e8cf05839cda2b4c30419cf2a53e60304be9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733351400,
      "headline": "Columbia Dividend Income Fund Q3 2024 Commentary",
      "id": 131773107,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365758819/image_1365758819.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Institutional Class shares of Columbia Dividend Income Fund returned 8.12% for the \nquarter ending September 30, 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=00f44478a7c2c5c5bdfac13b4f48e8cf05839cda2b4c30419cf2a53e60304be9"
    }
  },
  {
    "ts": null,
    "headline": "Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC",
    "summary": "This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.",
    "url": "https://finnhub.io/api/news?id=ee5950b03d2aa7bef7cd7f6bd336147f0293d19d6bc4c1d539bf8dd974556ffa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733334000,
      "headline": "Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC",
      "id": 131769558,
      "image": "https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.",
      "url": "https://finnhub.io/api/news?id=ee5950b03d2aa7bef7cd7f6bd336147f0293d19d6bc4c1d539bf8dd974556ffa"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=08daf689089102c06961ac01bec8b100fd6ce0d1634d6669dd75dadab45f94da",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733330040,
      "headline": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
      "id": 131775418,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=08daf689089102c06961ac01bec8b100fd6ce0d1634d6669dd75dadab45f94da"
    }
  },
  {
    "ts": null,
    "headline": "Why Is AbbVie Inc. (ABBV) Among the Dividend Kings You Should Consider?",
    "summary": "We recently compiled a list of the Dividend Kings List: Top 15. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other dividend kings you should know about. Dividend Kings are a distinguished group of companies that have achieved at least 50 consecutive years of dividend increases. […]",
    "url": "https://finnhub.io/api/news?id=81287efb6022f08fbde4fe4dadfe0fb49b3bafeeb09e1b44d9c1998700116a1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733318512,
      "headline": "Why Is AbbVie Inc. (ABBV) Among the Dividend Kings You Should Consider?",
      "id": 131796679,
      "image": "https://s.yimg.com/ny/api/res/1.2/m1YYSOl9HO_x0LHuYGlC8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Dividend Kings List: Top 15. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other dividend kings you should know about. Dividend Kings are a distinguished group of companies that have achieved at least 50 consecutive years of dividend increases. […]",
      "url": "https://finnhub.io/api/news?id=81287efb6022f08fbde4fe4dadfe0fb49b3bafeeb09e1b44d9c1998700116a1a"
    }
  }
]